Comparing Gemcitabine Plus BCG Versus BCG Alone for Recurrent High-Grade Non-Muscle Invasive Bladder Cancer
A Randomized Phase III Trial Evaluating Treatment Effectiveness and Safety
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-10-02
330
Participants Needed
60
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding gemcitabine to intravesical Bacillus Calmette Guerin BCG treatment improves outcomes for patients with recurrent non-muscle invasive bladder cancer NMIBC after prior BCG therapy. This phase III trial compares the combination of gemcitabine, a chemotherapy drug that blocks DNA production, with standard BCG treatment alone. The study aims to assess differences in cancer recurrence, progression, and safety between these treatments.
Participants are randomly assigned to one of two groups. One group receives BCG alone, administered intravesically once weekly for six weeks, followed by additional weekly doses at months 3, 6, and 12 if there is no disease progression or unacceptable side effects. The other group receives a combination of gemcitabine and BCG given intravesically on a specific schedule over 10 weeks, with maintenance doses of both drugs at months 3, 6, and 12 under similar conditions. Both groups undergo bladder biopsies, cystoscopy, TURBT procedures, CT or MRI scans, and blood and urine sample collection throughout the study.
After completing treatment, participants are followed every three months for two years, then every six months for up to five years from randomization. Researchers monitor high-grade recurrence-free survival as the primary outcome, along with secondary measures such as cancer-free status at three months, complete response rates, durability of response, time to any bladder cancer recurrence, progression-free survival, cystectomy-free survival, and safety through adverse event rates. The study also collects tumor tissue and biological samples for future research.
CONDITIONS
Brief Title
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Research Team
A
Aishwarya Vijendran
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
BCG Plus Gemcitabine
BCG Alone
What it is
Combination of intravesical BCG and intravesical gemcitabine, both given as bladder instillations following resection
Intravesical Bacillus Calmette-Guérin (BCG), given as bladder instillation after tumor resection
Role in the trial
Investigational arm—participants receive BCG plus gemcitabine after tumor resection
Active comparator arm—participants receive standard BCG following induction-resection procedures
Primary use
Prevention of recurrence of high-grade NMIBC after previous BCG exposure by combining two intravesical drugs
Prevention of recurrence of high-grade non-muscle invasive bladder cancer (NMIBC) after previous BCG exposure
How it is given
Both BCG and gemcitabine are instilled into the bladder through a catheter after tumor removal.
BCG is instilled directly into the bladder through a catheter after tumor resection.
Evidence status
Clinical trial evidence for adding gemcitabine to BCG is emerging; prior early-phase studies suggest possible longer recurrence-free survival, but outcomes in this population are still under investigation.
BCG is supported by longstanding clinical evidence and is recommended in guidelines as initial and repeat therapy for NMIBC.
Important limitations
Safety and efficacy in larger, randomized populations are not yet determined; combination therapy may have increased bladder symptoms such as irritation or discomfort.
A significant proportion of patients experience recurrence after BCG, and some become BCG-unresponsive, requiring alternative approaches.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Histologic confirmation of high-grade urothelial carcinoma (Ta, T1, or carcinoma in situ) within 120 days before randomization
All visible bladder tumors removed by TURBT within 90 days before randomization
Restaging TURBT required for high-grade T1 within 90 days before randomization
Recurrent high-grade non-muscle invasive bladder cancer within 24 months of last BCG exposure but not BCG-unresponsive
Prior intravesical chemotherapy or systemic agents for bladder cancer allowed
HIV-positive patients on effective therapy with undetectable viral load within 6 months
Age 18 years or older
Patients with prior or concurrent cancers allowed if not interfering with study assessments
Not pregnant or breastfeeding; negative pregnancy test required for those of childbearing potential
You will not qualify if you...
Any neuroendocrine carcinoma component present
Pure squamous cell carcinoma or pure adenocarcinoma without urothelial component
History or current evidence of muscle-invasive, locally advanced unresectable, or metastatic bladder cancer
History of intolerance to BCG or other intravesical therapies
Compromised bladder function preventing further intravesical treatments
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 12 months
Participants receive either BCG alone intravesically once weekly for 6 weeks with maintenance doses at months 3, 6, and 12, or a combination of gemcitabine and BCG given intravesically on a detailed schedule over 10 weeks with maintenance doses at months 3, 6, and 12 if no disease progression or unacceptable toxicity occurs. Participants also undergo bladder biopsies, TURBT, cystoscopy, CT or MRI scans, and blood and urine samples during treatment.
Follow-up
Duration - Up to 5 years
After treatment, participants are followed every 3 months for 2 years, then every 6 months for up to 5 years to monitor cancer recurrence and safety.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
A Scalable Program Increasing Cruciferous Vegetable Intake to Reduce Recurrence and Progression in Non-Muscle Invasive Bladder Cancer
EMPOWER Trial Comparing a Home-Based Physical Activity Program Using the ExerciseRx App to Health Education for Adults with Non-Muscle Invasive Bladder Cancer
Cancer CARE Beyond Walls In-home Intravesical Therapy for Non-Muscle Invasive Bladder Cancer Phase IbII Single-Arm Trial Comparing Home and Clinic Chemotherapy Delivery
Phase I Study of PLZ4-Coated Paclitaxel Micelles Delivered into the Bladder for Recurrent or Treatment-Resistant Non-Muscle Invasive Bladder Cancer
Comparing Gemcitabine Plus BCG Versus BCG Alone for Recurrent High-Grade Non-Muscle Invasive Bladder Cancer
A Randomized Phase III Trial Evaluating Treatment Effectiveness and Safety
Comparing Pembrolizumab Plus Radiation to Chemotherapy Plus Radiation for High-Grade T1 Bladder Cancer in a Phase II Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A Phase I Clinical Trial of Chemoimmunotherapy With Alternating Intravesical Gemcitabine and Bacillus Calmette-Guérin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer.
Christopher D Gaffney, Syed Muneeb Alam, Gal Wald...